Friday, July 10, 2026

pharma · Motor fluctuations in advanced Parkinson’s disease · Non Cystic Fibrosis Bronchiectasis

ZAMBON S.P.A

ZAMBON S.P.A clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

IT HQ
8 Employees
EMA registrant Type
Company details
Status
Public
HQ
IT
Employees
8
Programs
3
Drugs
7
Patents
0
Intelligence · Clinical Programs

ZAMBON S.P.A projects

3 ClinicalTrials.gov programs sponsored by ZAMBON S.P.A.

ZAMBON S.P.A has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. CMS

    Zambon SpA

    Non Cystic Fibrosis Bronchiectasis

    phase 3 small molecule completed

    1 trial
  2. Liposomal Ciclosporin A, Liposomal Ciclosporin A

    Zambon SpA

    Bronchiolitis Obliterans Syndrome in Patients post Single or post Double Lung Transplantation

    phase 3 small molecule active

    1 trial
  3. ZB203L01

    Zambon SpA

    Motor fluctuations in advanced Parkinson’s disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does ZAMBON S.P.A have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.